Press coverage about Intrexon Corporation (NYSE:XON) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Intrexon Corporation earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6390127435588 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Intrexon Corporation to Post Q3 2017 Earnings of ($0.23) Per Share, Griffin Securities Forecasts (XON) (americanbankingnews.com)
- Intrexon Corporation (XON) Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share (americanbankingnews.com)
- Insider Buying: Intrexon Corporation (XON) COO Acquires 2,000 Shares of Stock (americanbankingnews.com)
- Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares (finance.yahoo.com)
Shares of Intrexon Corporation (NYSE XON) opened at 17.30 on Friday. The stock’s 50 day moving average price is $21.96 and its 200 day moving average price is $21.83. Intrexon Corporation has a 12-month low of $17.05 and a 12-month high of $32.90. The firm’s market capitalization is $2.08 billion.
Intrexon Corporation (NYSE:XON) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. During the same quarter in the previous year, the company posted ($0.42) EPS. Intrexon Corporation’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts expect that Intrexon Corporation will post ($0.87) earnings per share for the current year.
XON has been the topic of a number of research reports. Zacks Investment Research raised Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Tuesday, May 2nd. BidaskClub raised Intrexon Corporation from a “strong sell” rating to a “sell” rating in a report on Thursday, June 15th. Finally, Northland Securities set a $30.00 target price on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Intrexon Corporation presently has a consensus rating of “Hold” and a consensus price target of $37.60.
In other Intrexon Corporation news, CEO Randal J. Kirk purchased 132,625 shares of the stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $18.85 per share, with a total value of $2,499,981.25. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Andrew J. Last purchased 2,000 shares of the stock in a transaction on Monday, August 14th. The shares were acquired at an average cost of $19.99 per share, with a total value of $39,980.00. Following the transaction, the chief operating officer now directly owns 2,000 shares in the company, valued at $39,980. The disclosure for this purchase can be found here. In the last three months, insiders bought 141,719 shares of company stock valued at $2,669,554. 55.10% of the stock is currently owned by corporate insiders.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.